Zelira Therapeutics Ltd (PK) (ZLDAF)

thanks for posting.
This has taken such a hammering... is there any light at the end of the tunnel?

ZLDAF: effective April 14,2022 a one for 175 reverse split:

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes

Medical cannabis company Zelira shifts HQ to Plymouth Meeting from Australia
https://www.bizjournals.com/philadelphia/news/2021/03/09/zelira-therapeutics-medical-cannabis-philadelphia.html

https://mforum.com.au/cannabis-research-forges-on/

Why is something like High Tide jumping past few months... and we aren't? Where are we going wrong? Medicinal is skyrocketing in US... and will continue... I hope we're due soon.

How about a partnership with Trulieve... who is heavy in Fl, I believe... they're happy we're on the Roundtable, after all...

Friends,

Cannabis markets across North America are booming. This week we shared updates from BDSA on several mature and newer markets for January as well as data from Illinois for the month of February. Growth was strong across the board, with acceleration in California, which grew 28.6% from a year ago, and extremely vigorous gains from a year ago in the most mature markets of Colorado and Oregon, which increased 35.5% and 48.2%, respectively. Also, on Friday evening, Florida data revealed that the number of medical patients has surpassed 500K, or 2.3% of the entire population. In the most recent week, growth from a year ago was 55%.

Florida's growth has been aided by the addition of telehealth last year and perhaps as well the recent introduction of edibles. Another factor may be population growth during the pandemic. The state doesn't report revenue. Instead, it shares weekly data on units dispensed, which has grown substantially faster than the patient count. Year-to-date, medical cannabis units dispensed have increased by 84% compared to the same period a year ago, while flower sales have grown 139%. This marks a gain from Q4 for medical cannabis products, which grew 75% from the prior year. Flower sales were just ramping up in late 2019, and that growth has slowed from 189% but remains extremely strong.

As we think about how the rest of 2021 might play out across America, we are quite optimistic that the robust revenue growth will continue. Of course, each market is unique, and states will grow at different rates. We have some concern that overall per capita consumption rates could decline somewhat mid-year compared to a year ago due to heightened demand during the pandemic and non-recurring stimulus checks, but several factors are likely to overwhelmingly offset any potential slowdown in same-person consumption.

We think one of the biggest drivers of legal cannabis market growth is the shift from the illicit market. The pandemic proved to be very helpful on this front, as states which had previously not permitted delivery or curbside pickup did so, and this changed the market in a big way. Consumers can now order cannabis online the same way they order other goods, something the illicit market can't match. The very solid growth in mature Western states, especially for flower, is a sign that the legal market is continuing to convert illicit market consumers.

New markets opening are another growth driver, and this year Arizona has already quickly permitted adult-use sales. New Jersey is ramping up its medical program and will add adult-use later this year. Virginia, which just began sales to patients in late 2020, will be continuing to roll out its medical program, and it will also be adding flower, which should boost demand.

Growth in markets that are already legal for adult-use can often be constrained at first, limited by not enough supply and/or not enough points of distribution. So, newly legal markets, like California, Illinois, and Michigan, all of which have had constraints, have the ability to exhibit strong growth for a sustained period of time as the infrastructure continues to come online. This can be the case in medical markets as well, like Pennsylvania.

For public companies, the recent uptick in M&A points to even faster growth than the organic growth rates the overall legal cannabis industry will generate. The deals being done appear to be very accretive to the acquiring companies, and we continue to expect substantial tuck-in acquisitions ahead in this highly fragmented industry.

The legal cannabis industry is in its early days, with new markets opening and existing ones continuing to ramp up as supply and distribution expands. Even in the most mature markets, there is ample evidence that legal operators are taking share from the illicit market as well. Look for the industry to continue to generate strong growth over the balance of 2021.

Got it... I hope we have a strong proof of concept with Zenivol or Hope and get bought out... damn... give us .30/share I'll take it... the wait these past 3 yrs - let's do this

Comment section after cannabis article recommended ZLDAF as a promising investment idea.

Ack, what was mention about?

Seriously? When my Barron's subscription stops... literally, last Sun LMAO

Thanks... will try to google.

ZLDAF mentioned in comment in Barron's today.

thanks for that, MIMadman....

The Week In Cannabis:4:43 pm ET December 18, 2020 (Benzinga)

Zelira Therapeutics (ASX:ZLD) (OTCQB: ZLDAF) inked a licensing deal with Washington DC-based Alternative Solutions to produce and distribute HOPE throughout the district. Dr. Oludare Odumosu, CEO and Managing Director of USA for Zelira, told Benzinga that Zelira’s search for a DC license partner for HOPE was much more strategic than simply having visibility in the nation’s capital, and is a tentpole for Zelira’s overall US growth efforts for 2021.

“This latest partnership with Alternative Solutions aligns with Zelira’s long-stated mission to work with market leaders in each approved market to expand access to HOPE across the US,” said Odumosu. The first products are set to debut on Washington DC dispensary shelves in the Spring of 2021.

MADlONG2029

Nice

Barchart Technical Opinion
STRONG BUY
The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

https://www.barchart.com/stocks/quotes/ZLDAF/overview

MADLONG2029

I was researching any company within the cannabis sector in May of 2020 and bought in here at .031.

MADLONG2029

How'd you both find this company? Curious

"Looking for .30-.50 cents..." that would be very nice, Nonameface13, and I am hoping we are all going to get that...

Laying the preliminary groundwork... research research research... just now started to commercialize stuff... never very clear with revenue numbers... I'm hoping we will see hard numbers with regard to Zenivol, Hope products, etc.

Bigger hope is data packets are created with their trials... and they eventually apply for FDA authorization with any of their medicines...

Let's see... there's def. a possibility for big upside here...

Originally, their partnership with CHOP on Autism is what sold me early on to buy in...

Do you remember what they did back in the day?

MADLONG2029

Been long for yrs... before this was OTC in US... I had to friggin CALL to buy shares LOL... unfort. that's when it was around 11.5 USD cents or so...

Anyway, I'm long. Looking for .30-.50 cents... hopefully 2021.

Recovered very well from the dip...

I'm starting to see a pattern form.

Holding long!

MADLONG2029

Barchart Top 1% Buy!!!

https://www.barchart.com/stocks/quotes/ZLDAF/overview

MADLONG2029

Zelira Therapeutics Expands HOPE™ Distribution In The US Through Licensing Agreement With Alternative Solutions In Washington DC
PR Newswire - PRF - Tue Dec 15, 10:52AM CST

PHILADELPHIA , Dec. 15, 2020 /PRNewswire/ -- Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF), a global leader in the development of clinically validated cannabis medicines, is pleased to announce it has entered into a binding licensing agreement with Alternative Solutions, a licensed grower, manufacturer and distributor of medical cannabis products in the District of Columbia ( Washington DC ). Under the agreement, Alternative Solutions will produce and distribute the HOPE™ line of products, Zelira's top-selling treatment developed for autism patients, throughout the legal DC medical cannabis market beginning in Q2 2021.

Alternative Solutions will produce and distribute the HOPE™ line, Zelira's product developed for autism patients.

"Alternative Solutions is a leader in the DC medical cannabis market, and we couldn't have a better partner to launch HOPE™ in the nation's capital," says Dr. Oludare Odumosu , CEO & Managing Director USA for Zelira. "We are particularly excited about this partnership because Washington DC's MMJ reciprocity will allow legal access of HOPE™ to more patients across the country than ever before."

Washington DC has reciprocity with 32 other states in the US with approved medical cannabis programs. This expands access to patients registered in those states, as they are able to legally purchase medical cannabis products at an approved dispensary in Washington DC . HOPE™ is currently available in Pennsylvania , through an exclusive license agreement with Ilera Healthcare, and in Louisiana , through an agreement with Advanced Biomedics LLC.

"Alternative Solutions is thrilled to be partnering with Zelira to bring the HOPE™ product line to the Washington DC medical cannabis market," says Matt Lawson-Baker , Alternative Solutions CEO. "Access to this medicine in the nation's capital will provide patients and their families the treatment they deserve through a legal regulated medical cannabis program."

About Zelira Therapeutics (zeliratx.com)
Zelira Therapeutics Ltd is a leading global therapeutic medical cannabis company with access to the world's largest and fastest growing cannabis markets. Zelira owns a portfolio of proprietary revenue generating products and a pipeline of candidates undergoing clinical development that are positioned to enter global markets from 2020. The company is focused on developing branded cannabis products for the treatment of a variety of medical conditions including insomnia, autism and chronic non-cancer pain.

Zelira has two proprietary formulations under the HOPE™ brand that are generating revenues in Pennsylvania and have been licensed in Louisiana with other states in the US expected to follow. Zelira has also developed Zenivol™, a leading cannabinoid-based medicine for treatment of chronic insomnia, which successfully completed the world's first Phase 2a clinical trial for chronic insomnia.

Zelira conducts this work in partnership with world-leading researchers and organizations including Curtin University in Perth , Western Australia ; the Telethon Kids Institute in Perth ; the University of Western Australia , in Perth ; St. Vincent's Hospital in Melbourne, Australia ; and the Children's Hospital of Philadelphia (CHOP) in the United States.

IMO one of the hidden gems in the cannabis sector!

MADLONG2029

up again this Monday morning in Australia:

John thank you for the article, I haven't been able to due much DD. Just ran across it a few months ago and scoped up a nice tall stack.

May buy more at the next dip...

Paying the money exchange fee sucked at the time, however at 150% growth I can live with the $12.50 fee!!!!

MADLONG2029

Research shows that cannabinoids will play a major role in the future of oral care, and Zelira was the perfect partner.

SprinJene® CBD Toothpaste is a proprietary toothpaste formulation developed by SprinJene® CEO and Founder Dr. Sayed Ibrahim and Zelira Therapeutics, a global therapeutic medical cannabis company focused on developing branded cannabis products for the treatment of a variety of medical conditions such as insomnia, autism and chronic non-cancer pain.

Research shows that incorporating CBD into oral/dental care results in health benefits such as: naturally eliminating decay-causing bacteria, reducing gum inflammation, restoring pH balance and increasing remineralization, reducing bone loss associated with gum disease, and helping to improve overall health.

https://www.weedstreet420.com/press-release/sprinjene-cbd-toothpaste-hits-shelves-in-united-states-2020/

I agree, is anyone aware of where they are at in the FDA approval process?

MADLONG2029

moved up nicely in recent times... nice times ahead...

Yup - I'm still invested though... this co. doesn't post revenue numbers... great partnerships, but no numbers... wonder if we can expect numbers within the next couple months?

BIG silence around here....

Sequoia Financial Group Initiates Research Coverage on Zelira Therapeutics with Strong Buy Recommendation and a $0.14 Price Target

https://zeliratx.com/wp-content/uploads/2020/08/ZLD_200819_Sequoia_Initiation_Strong-Buy.pdf

Zelira Therapeutics Ltd (ASX: ZLD, OTCQB: ZLDAF), a global leader in the development of clinically validated cannabinoid medicines, is pleased to announce the initiation of research coverage of the company by Sequoia Financial Group.

Highlights:
Sequoia initiates coverage with STONG BUY recommendation
12 month price target of $0.14
Forecasts based on a conservative estimates of the market potential for HOPE™ (autism) and Zenivol™ (insomnia) only.
Valuations will be revised as additional drugs from the Zelira pipeline are launched into global markets.
Sequoia considers Zelria one of the most exciting stocks in the Australian medicinal cannabis sector.
Recent merger with US-based Ilera Therapeutics seen as a game changer and a key catalyst to accelerate the path to revenues.

Google it dude: https://clients3.weblink.com.au/pdf/ZLD/02256495.pdf

Second page...

Link?

Halted - US Licensing Deal... GL

If we're not at 30 cents by end-of-yr I'd be surprised... looking for an unusual run to .50 / $1

Good luck to all

Would be good to know who Zelira is discussing this with.

Zelira Therapeutics in discussions to license medicinal cannabis products in US

https://www.proactiveinvestors.com.au/companies/news/918457/zelira-therapeutics-in-discussions-to-license-medicinal-cannabis-products-in-us-918457.html

https://clients3.weblink.com.au/pdf/ZLD/02223052.pdf

https://clients3.weblink.com.au/pdf/ZLD/02223484.pdf

This has to go somewhere...

DA Finally Sends Overdue CBD Enforcement Update To Congress

https://www.marijuanamoment.net/fda-finally-sends-overdue-cbd-enforcement-update-to-congress/

"...while FDA takes potential steps to establish a clear regulatory pathway."

ZLDA finished UP 7.32% ,VOL 1,566,009 on AUX
today.

Agree with FDA if they require regulation to cbd.I think its coming.

Also,yes,CHOPS is huge in time with Zelira.

The article you posted a few days ago brings the power of Zeliras patents to the forefront,as far as being acquired.

Looking forward to the days ahead.

I can't see acquisition until they can prove value with their IP (e.g. sales)... more importantly, as I believed, their value will skyrocket if FDA begins to regulate CBD and calls for clinical validation of products...

I think we need both or the latter to see acquisition... then, .50-$1+ is possible...

Need the end of this year to see what'll come

Hopefully something because I'm getting smashed with XXII

The CHOP/Autism collaboration is big IMO... CHOP being renowned...

Care to speculate on what Zelira share price will do

if company is acquired ?

https://beforeitsnews.com/financial-markets/2020/02/zelira-therapeutics-fully-enrols-cannabis-clinical-trial-3329740.html

Wonder when Zelira will give us updates,and forward plans with Australias TGA, and,or Germanies governing medical body
concerning certification on insomnia,or opioid addiction?

Here is a good look into Australias top 20 in this field.

We are at # 14

https://www.businessnewsaus.com.au/articles/australia-s-top-20-cannabis-companies.html

Excellent article.Thanks.

Zelira is worshipping at the FDA altar hoping it will smite enemies

https://stockhead.com.au/health/zelira-is-worshipping-at-the-fda-altar-hoping-it-will-smite-enemies/

Here is to .50+!

Would be nice

once full report for ZLD 101 is done,to submit to FDA and get a Fast Track designation.

In the meantime,I feel over the counter sales will be huge.